Chemical Properties:
Package: Fluorinated Bottle, Aluminum foil bag, 25kg/Drum, or according to customer's requirement Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moistureCommercial Supply (CAS: 177036-94-1) Related Intermediates: CAS: 177036-94-1 Methyl 2-Hydroxy-3-Methoxy-3,3-Diphenylpropanoate CAS: 178306-47-3 2-Hydroxy-3-Methoxy-3,3-Diphenylpropanoic Acid CAS: 178306-51-9 (S)-2-Hydroxy-3-Methoxy-3,3-Diphenylpropionic Acid CAS: 178306-52-0 L-Proline Methyl Ester Hydrochloride CAS: 2133-40-6 4,6-Dimethyl-2-(Methylsulfonyl)pyrimidine CAS: 35144-22-0| Item | Specifications |
| Appearance | White Powder |
| Identification | IR |
| Loss On Drying | ≤1.00% |
| Residue on Ignition | ≤0.10% |
| Chromatographic Purity | |
| Single Impurity | ≤0.50% |
| Total Impurities | ≤1.00% |
| Purity | ≥99.0% |
| Heavy Metals | ≤20ppm |
| Test Standard | Enterprise Standard |
| Usage | Intermediate of API (CAS: 177036-94-1) |
Description:
Specifications:
Package & Storage:
| Chemical Name | Methyl 2-Hydroxy-3-Methoxy-3,3-Diphenylpropanoate |
| Synonyms | 2-Hydroxy-3-Methoxy-3,3-Diphenylpropanoic Acid Methyl Ester |
| CAS Number | 178306-47-3 |
| CAT Number | RF-PI160 |
| Stock Status | In Stock, Production Scale Up to Tons |
| Molecular Formula | C17H18O4 |
| Molecular Weight | 286.32 |
| Density | 1.176 |
| Brand | Ruifu Chemical |
Advantages:
FAQ:
Application:
Methyl 2-Hydroxy-3-Methoxy-3,3-Diphenylpropanoate (CAS: 178306-47-3), Intermediate of API (CAS: 177036-94-1). (CAS: 177036-94-1) is a selective endothelin-A (ETA) receptor antagonist introduced for the oral treatment of patients with pulmonary arterial hypertension (PAH), to improve exercise capacity and delay clinical worsening. PAH is a rare disease of the small pulmonary arteries characterized by vascular proliferation and remodeling, resulting in a progressive increase in pulmonary vascular resistance and pulmonary arterial pressure, and ultimately, right ventricular failure and premature death. Early symptoms of PAH include gradual onset of shortness of breath, fatigue, palpitation, edema, and fainting.
